Validation of Cell-Based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS
Part III – Analytical Issues

Authors & Contributors

Brent Wood - Dragan Jevremovic - Marie C. Béné - Ming Yan - Patrick Jacobs - Virginia Litwin

First Published

10 September 2013

Publisher

Wiley

DOI

Abstract

Clinical diagnostic assays, may be classified as quantitative, quasi-quantitative or qualitative. The assay's description should state what the assay needs to accomplish (intended use or purpose) and what it is not intended to achieve.

 

The type(s) of samples (whole blood, peripheral blood mononuclear cells (PBMC), bone marrow, bone marrow mononuclear cells (BMMC), tissue, fine needle aspirate, fluid, etc.), instrument platform for use and anticoagulant restrictions should be fully validated for stability requirements and specified.

 

When applicable, assay sensitivity and specificity should be fully validated and reported; these performance criteria will dictate the number and complexity of specimen samples required for validation. Assay processing and staining conditions (lyse/wash/fix/perm, stain pre or post, time and temperature, sample stability, etc.) should be described in detail and fully validated.

 

© 2013 International Clinical Cytometry Society

This article continues in full online at Wiley Online Library - use 'continue reading' button below

(opens as a new browser tab)